RedHill Biopharma Ltd – (RDHL) Expected to Announce Earnings of -$0.65 Per Share

Equities research analysts expect RedHill Biopharma Ltd – (NASDAQ:RDHL) to report earnings of ($0.65) per share for the current quarter, Zacks reports. Three analysts have made estimates for RedHill Biopharma’s earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.50). RedHill Biopharma posted earnings per share of ($0.70) during the same quarter last year, which suggests a positive year-over-year growth rate of 7.1%. The company is scheduled to announce its next earnings results on Thursday, February 22nd.

On average, analysts expect that RedHill Biopharma will report full year earnings of ($2.71) per share for the current year, with EPS estimates ranging from ($2.90) to ($2.52). For the next year, analysts forecast that the firm will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.60) to ($1.80). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for RedHill Biopharma.

RedHill Biopharma (NASDAQ:RDHL) last issued its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.18).

A number of brokerages recently commented on RDHL. Zacks Investment Research upgraded RedHill Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, September 27th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target (up from $33.00) on shares of RedHill Biopharma in a report on Wednesday, October 4th. Roth Capital reiterated a “buy” rating and set a $27.00 price target on shares of RedHill Biopharma in a report on Wednesday, October 4th. Finally, Seaport Global Securities began coverage on RedHill Biopharma in a report on Friday, October 6th. They set a “buy” rating and a $19.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $21.10.

Shares of RedHill Biopharma (NASDAQ:RDHL) traded down $0.05 during trading on Monday, reaching $5.17. The company had a trading volume of 48,300 shares, compared to its average volume of 130,491. The company has a market capitalization of $109.98, a price-to-earnings ratio of -1.91 and a beta of 1.01. RedHill Biopharma has a 1-year low of $4.30 and a 1-year high of $11.25.

Several institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning bought a new stake in shares of RedHill Biopharma in the fourth quarter valued at $722,000. Family Management Corp raised its stake in shares of RedHill Biopharma by 46.6% in the third quarter. Family Management Corp now owns 37,750 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 12,000 shares during the period. D.A. Davidson & CO. raised its stake in shares of RedHill Biopharma by 10.0% in the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 4,000 shares during the period. Oppenheimer & Co. Inc. raised its stake in shares of RedHill Biopharma by 10.8% in the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock valued at $220,000 after buying an additional 2,500 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of RedHill Biopharma by 13.6% in the second quarter. Bank of New York Mellon Corp now owns 12,005 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 1,440 shares during the period. Hedge funds and other institutional investors own 8.47% of the company’s stock.

TRADEMARK VIOLATION WARNING: “RedHill Biopharma Ltd – (RDHL) Expected to Announce Earnings of -$0.65 Per Share” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3144593/redhill-biopharma-ltd-rdhl-expected-to-announce-earnings-of-0-65-per-share.html.

About RedHill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on RedHill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.